|
Tempest Therapeutics, Inc. (TPST): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Tempest Therapeutics, Inc. (TPST) Bundle
In the cutting-edge world of precision oncology, Tempest Therapeutics emerges as a pioneering biotech company transforming cancer treatment through innovative molecular targeting strategies. By developing groundbreaking therapies like TPST-1495 and TPST-1120, this South San Francisco-based enterprise is pushing the boundaries of personalized cancer care, offering hope to patients through advanced scientific research and strategic drug development. Their focused approach on liver cancer and solid tumor treatments represents a critical evolution in targeted therapeutic interventions, promising potentially revolutionary breakthroughs in how we understand and combat complex malignancies.
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Product
Precision Oncology Therapeutics
Tempest Therapeutics focuses on developing targeted cancer therapies with specific molecular approaches.
| Product | Type | Target | Development Stage |
|---|---|---|---|
| TPST-1495 | Oral small molecule | Multiple cancer pathways | Preclinical/Phase 1 |
| TPST-1120 | Immunotherapy | Tumor microenvironment | Phase 1/2 |
Key Product Characteristics
- Concentration on liver cancer treatments
- Targeting solid tumor therapies
- Personalized cancer care approach
Pipeline Focus Areas
Tempest Therapeutics' product portfolio emphasizes precision medicine with molecular-targeted interventions.
| Treatment Area | Specific Cancer Type | Therapeutic Approach |
|---|---|---|
| Liver Cancer | Hepatocellular Carcinoma | Targeted molecular therapy |
| Solid Tumors | Multiple Cancer Types | Pathway-specific intervention |
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Place
Headquarters Location
Located at 7000 Shoreline Court, Suite 275, South San Francisco, California 94080.
Research and Development Facilities
| Location | Facility Type | Research Focus |
|---|---|---|
| San Francisco Bay Area | Primary R&D Center | Oncology Drug Development |
Clinical Trial Distribution
Clinical Trial Locations:
- Multiple U.S. research centers across 12 states
- Approximately 25-30 active clinical trial sites
Market Targeting
| Geographic Market | Market Strategy | Primary Focus |
|---|---|---|
| North America | Direct pharmaceutical market penetration | Oncology therapeutics |
Distribution Channels
- Specialized oncology treatment centers
- Hospital pharmacies
- Specialty pharmaceutical distributors
Global Expansion Strategy
Potential International Markets:
- European Union pharmaceutical markets
- Select Asia-Pacific oncology treatment regions
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Promotion
Scientific Conference Presentations
As of 2024, Tempest Therapeutics participated in the following key oncology conferences:
| Conference | Date | Presentations |
|---|---|---|
| American Association for Cancer Research (AACR) | January 2024 | 2 research presentations |
| American Society of Clinical Oncology (ASCO) | June 2024 | 3 clinical trial data presentations |
Investor Relations Communications
Quarterly earnings reports for 2024 included:
- Q1 2024 earnings call on April 15, 2024
- Total investor communication events: 4 quarterly calls
- Investor presentation deck updates: 3 times in 2024
Digital Marketing Strategy
Digital marketing channels utilized in 2024:
| Channel | Reach | Engagement Rate |
|---|---|---|
| LinkedIn Professional Network | 12,500 oncology professionals | 3.7% |
| Targeted Medical Research Websites | 8,200 researchers | 2.9% |
Collaboration Announcements
Partnerships and collaborations in 2024:
- Academic partnerships: 2 new collaborations
- Pharmaceutical industry partnerships: 1 strategic alliance
- Research collaboration value: $3.2 million
Biotech Investment Community Engagement
Investment community interactions in 2024:
| Event Type | Number of Events | Total Participants |
|---|---|---|
| Investor Conferences | 4 | 350 institutional investors |
| Biotech Analyst Meetings | 6 | 125 financial analysts |
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Tempest Therapeutics reported:
- Cash and cash equivalents: $13.3 million
- Net loss: $24.9 million for the fiscal year 2023
- Research and development expenses: $18.5 million
Pricing Strategy Considerations
Current financial positioning indicates a pre-revenue biotechnology model with pricing strategy dependent on future drug development outcomes.
| Financial Metric | Amount | Year |
|---|---|---|
| Total Operating Expenses | $37.4 million | 2023 |
| Research Investment | $18.5 million | 2023 |
| Cash Runway | Estimated 9-12 months | 2024 |
Investment and Funding
Funding sources include:
- Venture capital investments
- Public market financing
- Total raised capital: $89.6 million
Potential Pricing Factors
Key pricing determinants for future therapeutic products:
- Clinical trial success rates
- FDA approval probability
- Comparative market treatment costs
- Potential insurance reimbursement models
Market Positioning Metrics
| Product Category | Estimated Market Value | Potential Pricing Range |
|---|---|---|
| Oncology Therapeutics | $150-$250 million | $50,000 - $150,000 per treatment course |